Overview
BCDI provides comprehensive, family-centered healthcare for people with bleeding and clotting disorders as a 501(c)(3) nonprofit. Its care model uses an integrated team—hematologists, nurses, therapists, social workers, and dietitians—plus on-site labs, an infusion suite, and an accredited pharmacy, with nine outreach clinics and expanding telemedicine to improve access. As Illinois’ only federally funded Hemophilia Treatment Center of Excellence outside Chicago, it combines patient care with active research through clinical trials at its Center for Research. The institute’s goal is to deliver accessible, evidence-based care that addresses physical, mental, and emotional needs while advancing treatment through research and community outreach.
Work here?Claim your company
Simplify's take
What believers are saying
- Downers Grove clinic should pull suburban referrals and reduce travel friction immediately.
- Open EMIVWD enrollment strengthens BCDI's research visibility and pharma partnering leverage this year.
- New physicians, Dr. Melinda Chance and Dr. Joanne McManaman, deepen capacity for 2026 growth.
What critics are saying
- BCDI relies heavily on Dr. Michael Tarantino; succession risk threatens continuity by 2027.
- Outreach-clinic expansion raises operating costs faster than donation and reimbursement growth in 2026.
- Specialized hemophilia referrals and federal funding concentration create an existential reimbursement shock risk.
What makes Bleeding and Clotting Disorders Institute unique
- BCDI remains Illinois' only federally designated hemophilia center outside Chicago.
- BCDI opened Downers Grove on May 13, 2026, expanding eleven Illinois outreach clinics.
- BCDI presented THSNA 2026 research, including EMIVWD emicizumab studies and sports guidance.
Help us improve and share your feedback! Did you find this helpful?